Eli Lilly received remarkably swift FDA approval this week for Foundayo (orforglipron), a once-daily oral pill designed for weight loss and obesity treatment. The approval, among the fastest in decades, marks a significant step forward in expanding access to these increasingly popular medications. Clinical trials showed the highest dose (36mg) led to an average weight loss of 27 pounds over 72 weeks—though this figure lags behind injectable alternatives.
The Expanding GLP-1 Landscape
Foundayo is the second oral GLP-1 drug to gain FDA clearance, following Novo Nordisk’s Wegovy pill (approved in 2025). The emergence of more options, both in pill and injectable form, is poised to reshape the market, potentially driving down costs and increasing patient convenience. Experts suggest that easier manufacturing and distribution of pills—compared to injectables—could reach a wider population.
How Foundayo Compares to Existing Treatments
The effectiveness of Foundayo varies with dosage. Trials revealed:
– 6mg dose: 5% body weight loss
– 12mg dose: 7% body weight loss
– 36mg dose: Nearly 10% body weight loss
For context, Wegovy’s 25mg pill caused roughly 17% weight loss over 64 weeks, while Eli Lilly’s injectable Zepbound (tirzepatide) resulted in up to 21% weight reduction after 72 weeks. While Foundayo doesn’t match these figures, it provides a viable alternative for patients seeking oral administration.
The Potential for Transitioning from Injections
Eli Lilly is actively researching whether patients who achieve weight loss with injectable GLP-1 drugs can transition to Foundayo and maintain their results. The data, submitted for peer review, will soon reveal if this approach is effective. This would address a key question for many patients: Can they move from injections to a more convenient pill without regaining weight?
Foundayo’s Mechanism and Advantages
Foundayo operates like other GLP-1 drugs (such as Wegovy) by activating receptors in the gut. This increases feelings of fullness and slows stomach emptying, leading to reduced food intake and weight loss. However, Foundayo distinguishes itself as a non-peptide small molecule.
Peptide-based drugs (like semaglutide in Wegovy) degrade quickly in the stomach, requiring special formulations and empty-stomach administration. Foundayo, being non-peptide, absorbs more efficiently regardless of food intake, offering greater flexibility. It’s also expected to be cheaper and easier to manufacture, eliminating cold storage and specialized pens.
Pricing and Availability
Eli Lilly lists Foundayo’s starting price at $25/month with commercial insurance and their savings card. Out-of-pocket costs range from $149 to $349/month depending on the dose. Medicare Part D recipients may access it for $50 starting in July. The drug will be available in doses from 0.8mg to 17.2mg, with titration schedules to minimize side effects.
Safety and Future Outlook
Clinical trials reported minor side effects—nausea, vomiting, diarrhea—but no major safety concerns. While GLP-1 drugs have been used for over two decades, monitoring for long-term effects is crucial. The FDA’s approval confirms Foundayo’s safety and efficacy based on robust clinical data.
The arrival of Foundayo and future GLP-1 candidates is likely to increase supply and gradually improve affordability. However, substantial price reductions will take time as the market matures.
The introduction of Foundayo signals a shift toward greater accessibility in the weight-loss drug market, offering patients more choices and potentially lowering costs in the long run.
